GeneNews closes warrant exercise incentive program

GeneNews (TSX:GEN) has completed an early warrant exercise incentive program and debenture conversion, raising almost $3 million. A total of 74% of eligible warrants were exercised and the company issued 12.8 million common shares and 12.8 million incentive warrants. In addition, holders of 25% of eligible convertible debentures participated in the debenture conversion, resulting in [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

GeneNews gets Malaysian seed grant

GeneNews (TSX:GEN) has received approval of a seed capital grant of about $625,000 from the Malaysian Biotechnology Corp. to support the commercial launch of its ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia. “Driving the global commercialization and clinical adoption of the ColonSentry test as an [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Study backs ColonSentry effectiveness

GeneNews (TSX: GEN) says that a poster describing a 786-patient study entitled “Blood RNA Biomarker Detects Both Left- and Right-sided Colorectal Neoplasms” has been accepted for presentation at the Next Generation Dx Summit in Washington, DC this week. The poster details the application of a seven-gene biomarker panel, which forms the basis of the company’s [...]

GeneNews completes deal to bring ColonSentry to China

GeneNews (TSX:GEN) has executed a formal marketing partnership agreement with GeneDiagnostics, a private clinical research and services company in China, to market ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer. Under the accord, GeneDiagnostics has obtained non-exclusive rights to market and sell the ColonSentry test in Shanghai and [...]

Malaysian study further validates GeneNews’ ColonSentry

A 210-patient Malaysian study entitled “Blood-based Seven-gene Biomarker Panel for Colorectal Cancer: Validation in Malaysia” has been presented at the 2010 National Committee for Clinical Research conference in Kuala Lumpur. GeneNews (TSX:GEN) said the seven-gene biomarker panel forms the basis of its lead ColonSentry product, the world’s first blood test for colorectal cancer.  The abstract [...]

GeneNews names Auld as CFO

GeneNews (TSX:GEN) has appointed Leslie Auld as CFO and treasurer, succeeding Sonny Young, who will continue to work with the company in a consulting capacity. Ms. Auld, who was retained by GeneNews as a financial consultant at the start of 2010, was most recently a consultant to Attwell Capital, formerly Fralex Therapeutics, and previously CFO [...]

Second U.S. patent awarded to GeneNews

GeneNews (TSX:GEN) was granted a second U.S. patent for its core Sentinel Principle platform technology, covering its application in any health management context, including diagnosis, staging of disease, drug testing, monitoring response to treatment and biomarker screening. “Together, these two patents form a strong foundation for our IP, protecting the application of our Sentinel Principle [...]

« Previous Page